Home › Compare › PBCRY vs ABBV
PBCRY yields 0.51% · ABBV yields 3.06%● Live data
📍 PBCRY pulled ahead of the other in Year 8
Combined, PBCRY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PBCRY + ABBV for your $10,000?
PT Bank Central Asia Tbk, together with its subsidiaries, provides banking products and services to individual, corporate, and small and medium enterprise customers in Indonesia and internationally. It offers savings accounts; motorcycle financing, as well as car, housing, working capital, and investment loans; mutual funds and bonds; electronic money services; credit cards; business collection services; and home and eBanking, remittance, and customer services. The company also provides investment financing, working capital financing, auto and multipurpose financing, operating lease, other financing activities, money lending and remittance, securities brokerage dealing and securities issuance underwriting, general or loss insurance, life insurance, Sharia banking, and venture capital services. As of December 2021, it operated 1,334 offices comprising 137 main branch offices; 1,105 permanent sub-branch offices; 70 mobile sub-branch offices; and 22 functional offices, as well as total 18,034 automated teller machines (ATMs) consisting of cash recycling machines and multi-functional ATMs. PT Bank Central Asia Tbk was founded in 1955 and is headquartered in Jakarta, Indonesia. PT Bank Central Asia Tbk is a subsidiary of PT Dwimuria Investama Andalan.
Full PBCRY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.